Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22660996 | 0.86 | THRB (0.38) | ALDH1A1LMNATSHR | |
| SCHEMBL27621433 | 0.85 | ALDH1A1 (0.54) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL8607642 | 0.84 | ALDH1A1 (0.44) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL10990505 | 0.84 | ALDH1A1 (0.56) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL9724865 | 0.84 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL6241547 | 0.83 | ALDH1A1 (0.45) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL4880627 | 0.81 | ALDH1A1 (0.46) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL561350 | 0.81 | SMN1; SMN2 (0.36) | ALDH1A1LMNACYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL31602103 | 0.80 | LMNA (0.52) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL1038859 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071287-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | SIGNAL PHARM LLC (US) | 2018-03-15 | — | — | US | disclosed |
| CN-101755240-A | Cleaning composition for removing resist | ANJI MICROELECTRONICS SHANGHAI | 2010-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071287-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | CYP11B2, CYP27A1, CYP11B1 | ALDH1A1 475/4885TDP1 1733/4885LMNA 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.